Profile
Robert Letellier founded PharmaGap, Inc. in 1999, where he worked as Director from 2010 to 2012 and AB Biotech, Inc. in 2004, where he is working as President, Chief Executive Officer & Director from 2011.
Mr. Letellier received his undergraduate degree from the University of Sherbrooke.
Robert Letellier active positions
| Companies | Position | Start |
|---|---|---|
AB Biotech, Inc.
 AB Biotech, Inc. Pharmaceuticals: MajorHealth Technology AB Biotech, Inc. develops and commercializes immunological products. It also develops an immunological approach to sexing semen for all species and humans. The company was founded by Robert Letellier in 2004 and is headquartered in Montréal, Canada. | Founder | 2010-10-20 |
Former positions of Robert Letellier
| Companies | Position | End |
|---|---|---|
PharmaGap, Inc.
 PharmaGap, Inc. BiotechnologyHealth Technology PharmaGap, Inc. engages in developing novel peptide therapeutics for the treatment of cancer. The company was founded by Robert Letellier, Jenny Phipps and Michel Phipps on October 6, 1999 and is headquartered in Ottawa, Canada. | Founder | - |
Training of Robert Letellier
| University of Sherbrooke | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
PharmaGap, Inc.
PharmaGap, Inc. BiotechnologyHealth Technology PharmaGap, Inc. engages in developing novel peptide therapeutics for the treatment of cancer. The company was founded by Robert Letellier, Jenny Phipps and Michel Phipps on October 6, 1999 and is headquartered in Ottawa, Canada. | Health Technology |
AB Biotech, Inc.
AB Biotech, Inc. Pharmaceuticals: MajorHealth Technology AB Biotech, Inc. develops and commercializes immunological products. It also develops an immunological approach to sexing semen for all species and humans. The company was founded by Robert Letellier in 2004 and is headquartered in Montréal, Canada. | Health Technology |
- Stock Market
- Insiders
- Robert Letellier
